Regulatory & Industry
| 5 min read
While faster reviews could bring life-saving treatments to patients sooner, compressed timelines could also limit regulatory scrutiny and strain FDA resources.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 5 min read
The life sciences sector contributes billions to the economy, but current policy and international factors are threatening growth.
| 3 min read
These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.
| 5 min read
Computational models are reshaping how therapies are discovered, tested, and optimized.
| 5 min read
Regulatory science is increasingly relying on modeling, simulation, and AI tools to accelerate drug development while maintaining safety and efficacy.
